• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Wednesday

    3/30/22 12:42:03 PM ET
    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABOS alert in real time by email

     

     

    On Wednesday, 29 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company in terms of market cap to set a new 52-week low was Tempur Sealy Intl (NYSE:TPX).
    • Stryve Foods (NASDAQ:SNAX) was the smallest company when considering market cap to set a new 52-week low.
    • Revelation Biosciences (NASDAQ:REVB) saw the most significant move of the companies, as shares traded down 40.67% to reach its new 52-week low.
    • Incannex Healthcare (NASDAQ:IXHL) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low.

    On Wednesday, the following stocks hit new 52-week lows:

    • Tempur Sealy Intl (NYSE:TPX) shares set a new 52-week low of $29.01. The stock traded down 4.94%.
    • Embecta (NASDAQ:EMBCV) stock set a new 52-week low of $38.00 on Wednesday, moving down 3.75%.
    • Cue Health (NASDAQ:HLTH) shares reached a new 52-week low of $6.42 on Wednesday morning, moving down 1.49%.
    • Aveanna Healthcare Hldgs (NASDAQ:AVAH) shares moved down 1.03% on Wednesday to hit a new 52-week low of $3.80, drifting down 1.03%.
    • Torrid Holdings (NYSE:CURV) stock hit a yearly low of $6.62. The stock was down 2.35% for the day.
    • Sight Sciences (NASDAQ:SGHT) shares set a new 52-week low of $12.66. The stock traded down 9.33%.
    • Arcellx (NASDAQ:ACLX) stock broke to a new 52-week low of $13.47 on Wednesday. Shares of the company traded down 0.71%.
    • Incannex Healthcare (NASDAQ:IXHL) shares made a new 52-week low of $9.30 on Wednesday. The stock was 0.0% (flat) for the day.
    • DWS Municipal IT (NYSE:KTF) stock broke to a new 52-week low of $10.01 on Wednesday. Shares of the company traded up 0.96%.
    • Anghami (NASDAQ:ANGH) stock achieved a new 52-week low on Wednesday morning, hitting $9.27 and moving down 0.84%.
    • Airspan Networks Hldgs (AMEX:MIMO) stock drifted down 1.95% on Wednesday morning to hit a new 52-week low of $2.83.
    • UpHealth (NYSE:UPH) stock achieved a new 52-week low on Wednesday morning, hitting $1.31 and moving down 29.79%.
    • Acumen Pharmaceuticals (NASDAQ:ABOS) stock hit a yearly low of $4.10. The stock was down 5.48% for the day.
    • Galiano Gold (AMEX:GAU) stock achieved a new 52-week low on Wednesday morning, hitting $0.52 and moving down 4.57%.
    • Kirkland's (NASDAQ:KIRK) stock hit a yearly low of $9.65. The stock was down 5.5% for the day.
    • Annexon (NASDAQ:ANNX) stock dropped to a yearly low on Wednesday of $2.91. Shares traded up 0.84%.
    • Accelerate Diagnostics (NASDAQ:AXDX) shares made a new 52-week low of $1.40 on Wednesday. The stock was down 5.07% for the day.
    • Applied Genetic (NASDAQ:AGTC) stock dropped to a yearly low on Wednesday of $1.10. Shares traded down 0.45%.
    • Inpixon (NASDAQ:INPX) shares set a new 52-week low of $0.24. The stock traded down 9.46%.
    • Coffee Holding Co (NASDAQ:JVA) shares set a new 52-week low of $3.40. The stock traded down 1.1%.
    • Revelation Biosciences (NASDAQ:REVB) shares set a new yearly low of $0.70 this morning. The stock was down 40.67% on the session.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock hit $1.42 on Wednesday morning, setting a new 52-week low for a change of down 3.94%.
    • Stryve Foods (NASDAQ:SNAX) stock achieved a new 52-week low on Wednesday morning, hitting $1.32 and moving down 10.0%.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $ACLX
    $AGTC
    $ANGH

    CompanyDatePrice TargetRatingAnalyst
    Aveanna Healthcare Holdings Inc.
    $AVAH
    3/20/2026$13.00Outperform → Strong Buy
    Raymond James
    Arcellx Inc.
    $ACLX
    2/12/2026$82.00Buy → Neutral
    Rothschild & Co Redburn
    Arcellx Inc.
    $ACLX
    1/7/2026$100.00Buy
    UBS
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Arcellx Inc.
    $ACLX
    12/22/2025$100.00Overweight
    Wells Fargo
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    Arcellx Inc.
    $ACLX
    11/18/2025Peer Perform
    Wolfe Research
    More analyst ratings

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    SEC Filings

    View All

    SEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.

    DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

    4/23/26 4:31:13 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Acumen Pharmaceuticals Inc.

    DEF 14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

    4/23/26 4:30:33 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    4/23/26 8:01:24 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Habib Elias

    3 - Anghami Inc (0001871983) (Issuer)

    4/23/26 9:13:21 AM ET
    $ANGH
    Telecommunications Equipment
    Consumer Discretionary

    SEC Form 4 filed by Gilson Michelle

    4 - Arcellx, Inc. (0001786205) (Issuer)

    4/17/26 5:00:14 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Dempsey Paula

    4 - Torrid Holdings Inc. (0001792781) (Issuer)

    4/15/26 4:18:43 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call

    ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 14, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13759633. The replay will be available until May 21, 2026. Intere

    4/23/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Sight Sciences Announces the Release of its Sustainability Report

    MENLO PARK, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company's sustainability activities, performance and results from the last three years. "We are proud to issue our third Sustainability Report, reflecting our continued progress in transparency, operational discipline, and environmental impact reduction, while reinforcing our commitment to creating long term value for all stakeholders," stated Paul Badawi, co-founder

    4/22/26 4:45:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

    MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, "Accelerating Medical Treatments for Serious Mental Illness." The Company believes its PSX-001 development program aligns with the goals outlined in the Executive Order and believes the data demonstrated to date, along with a more amenable regulatory environment, may provide significant hope for those suffering from anxiety disorders. "We agree with the Administration's recognition that

    4/22/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aveanna upgraded by Raymond James with a new price target

    Raymond James upgraded Aveanna from Outperform to Strong Buy and set a new price target of $13.00

    3/20/26 10:18:34 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Arcellx downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral and set a new price target of $82.00

    2/12/26 7:20:24 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Leadership Updates

    Live Leadership Updates

    View All

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

    NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to th

    11/10/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Financials

    Live finance-specific insights

    View All

    Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call

    ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 14, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13759633. The replay will be available until May 21, 2026. Intere

    4/23/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2026, after the market close on Wednesday, May 6, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at ww

    4/21/26 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Galiano Gold Provides Notice of First Quarter 2026 Results

    Vancouver, British Columbia--(Newsfile Corp. - April 10, 2026) - Galiano Gold Inc. (TSX:GAU) (NYSE:GAU) ("Galiano" or the "Company") is pleased to announce it will release its first quarter ("Q1") 2026 financial and operating results after market close on May 13, 2026. The Company will host a conference call and webcast to review the Q1 2026 results on May 14, 2026, at 7:30am PT.Conference Call DetailsDate:May 14, 2026Time:10:30am ET (7:30am PT)Dial In:1-647-932-3411Toll-Free:1-800-715-9871Conference IDID 9798035Replay Link:https://www.gowebcasting.com/14680  The conference call will be webcast https://www.gowebcasting.com/14680 and can be accessed on Galiano's website: galianogold.com.About

    4/10/26 8:30:00 AM ET
    $GAU
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials